"Founded in 1964, New York Blood Center (NYBC) is a nonprofit organization that is one of the largest independent, community-based blood centers in the world. NYBC, along with its operating divisions Community Blood Center of Kansas City, Missouri (CBC), Innovative Blood Resources (IBR), Blood Bank of Delmarva (BBD), and Rhode Island Blood Center (RIBC), collect approximately 4,000 units of blood products each day and serve local communities of more than 75 million people in the Tri-State area (NY, NJ, CT), Mid Atlantic area (PA, DE, MD, VA), Missouri and Kansas, Minnesota, Nebraska, Rhode Island, and Southern New England."

During the past decade, New York Blood Center CRS conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 7 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Blood Center CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 28 trials, followed by "Janssen Vaccines & Prevention B.V." with 3 trials sponsored, "New York Blood Center" with 3 trials sponsored, "Center for International Blood and Marrow Transplant Research" with 2 trials sponsored and "Centers for Disease Control and Prevention" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Blood Center CRS" #1 collaborator was "HIV Vaccine Trials Network" with 5 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "Department of Health and Human Services" with 2 trials as a collaborator and "National Cancer Institute (NCI)" with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "New York Blood Center CRS" are "HIV Infections" (31 trials), "Healthy" (3 trials), "Leukemia" (3 trials), "COVID-19" (2 trials) and "Graft Versus Host Disease" (2 trials). Many other conditions were trialed in "New York Blood Center CRS" in a lesser frequency.

Most popular intervention types in "New York Blood Center CRS" are "Biological" (33 trials), "Drug" (6 trials), "Behavioral" (5 trials), "Other" (5 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "VRC-HIVDNA009-00-VP" (3 trials), "ALVAC(2)120(B,MN)GNP (vCP1452)" (2 trials), "Ad26.Mos4.HIV" (2 trials) and "Sample collection" (2 trials). Other intervention names were less common.

The vast majority of trials in "New York Blood Center CRS" are 40 trials for "All" genders, 6 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "New York Blood Center CRS". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in New York Blood Center CRS, 2 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in New York Blood Center CRS, 23 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".